CytoSorbents appoints Jiny Kim to Board of Directors as independent director

Cytosorbents Corp

Appointment effective April 1, 2022; term expires at June 7, 2022 annual meeting, where she is expected to stand for re-election.
Board expanded from five to six members; Kim brings medical device experience from Zimmer Biomet, LivaNova, and Johnson & Johnson.
Kim currently VP at Zimmer Biomet leading Smart Implants portfolio, including launch of Persona IQ® smart knee implant.
She will receive standard non-employee director compensation; committee assignments not yet determined.
Company's CEO and Chairman cite her experience as valuable for U.S. expansion and potential FDA approval of DrugSorb™-ATR.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jiny Kim

Director

CTSO · Cytosorbents Corp

Effective: 2022-04-01
Filed: April 5, 2022, 7:59 PM ET

On April 1, 2022, the Board of Directors (the "Board") of CytoSorbents Corporation (the "Company") increased the size of the Board from five to six, and upon the recommendation of the Company’s Nominating and Corporate Governance Committee, appointed Ms. Jiny Kim to the Board to fill the resulting vacancy.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jiny Kim was appointed as Director at Cytosorbents Corp.

Action: appointed
Role: Director

Exact text from the filing

On April 1, 2022, the Board of Directors (the "Board") of CytoSorbents Corporation (the "Company") increased the size of the Board from five to six, and upon the recommendation of the Company’s Nominating and Corporate Governance Committee, appointed Ms. Jiny Kim to the Board to fill the resulting vacancy.

View on SEC.gov

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-042785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.